Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
49 巻, 17 号
選択された号の論文の19件中1~19を表示しています
EDITORIALS
ORIGINAL ARTICLES
  • Masaki Watanabe, Kouichi Inukai, Takashi Sumita, Kaori Ikebukuro, Dais ...
    2010 年 49 巻 17 号 p. 1843-1847
    発行日: 2010年
    公開日: 2010/09/01
    ジャーナル オープンアクセス
    Objective PPARγ agonists are widely used in type 2 diabetic patients to reduce insulin resistance. Recently, telmisartan, an AT1 receptor antagonist, was reported to function as a partial agonist of PPARγ based on in vitro experiments. The aim of the present study was to investigate whether the PPARγ enhancing activity of telmisartan is exerted clinically in diabetic patients.
    Methods We compared the effects of telmisartan with those of candesartan, on insulin sensitivity, the serum levels of various adipocytokines and oxidative stress.
    Patients In total, 85 Japanese type 2 diabetic patients with hypertension, maintained on 8 mg per day of candesartan, were randomly assigned to the TM group (candesartan switched to 40 mg of telmisartan, n=38) or the CD group (no treatment change, n=47).
    Results After 3 months, oxidized lipids were significantly decreased only in the TM group. Although the homeostasis assessment model of insulin resistance (HOMA-R) tended to be improved and serum concentrations of HDL-cholesterol and HMW adiponectin tended to be increased only in the TM group, these alterations were too small to be significant by unpaired t-test. Interestingly, in subgroup analysis, the alterations of HOMA-R, serum concentrations of oxidized lipids, and HMW adiponectin were more apparent in obese TM group subjects and the changes reached statistical significance.
    Conclusion Switching from candesartan to telmisartan in obese subjects increases serum adiponectin and improves both insulin resistance and oxidative stress, while these effects were not statistically apparent in the total patient population. These results support the idea that telmisartan exerts its PPARγ enhancing activity clinically in obese type 2 diabetic patients.
  • Kosaku Komiya, Haruyuki Ariga, Hideaki Nagai, Shinji Teramoto, Atsuyuk ...
    2010 年 49 巻 17 号 p. 1849-1855
    発行日: 2010年
    公開日: 2010/09/01
    ジャーナル オープンアクセス
    Objective This study evaluated the effect of peripheral lymphocyte count on 2 interferon-gamma release assays [QuantiFERON TB-Gold (QFT-G) and enzyme-linked immunospot (ELISPOT)] and their sensitivity in patients with pulmonary tuberculosis, including HIV-negative immunocompromised patients.
    Patients and Methods Two hundred thirty patients with microbiologically confirmed active pulmonary tuberculosis were subjected to the tests. Lymphocyte counts were analyzed simultaneously.
    Results Overall sensitivity was 74% (159/215; 95% CI, 68-80%) for QFT-G and 92% (198/215; 89-96%) for ELISPOT (p<0.0001). In patients with peripheral lymphocyte counts of ≥1000/μL, sensitivity was high for both QFT-G (88%, 111/126; 82-94%) and ELISPOT (97%, 122/126; 94-100%). However, the sensitivity decreased significantly with decreasing peripheral lymphocyte count for both QFT-G (test for trend p<0.0001) and ELISPOT (test for trend p=0.007). When lymphocyte counts were <500/μL, the sensitivity was 81% (25/31; 66-96%) for ELISPOT, but only 39% (12/31; 21-57%) for QFT-G.
    Conclusion Both QFT-G and ELISPOT are sensitive methods for detecting active pulmonary tuberculosis, but their sensitivity partly depends on peripheral lymphocyte counts. At low lymphocyte count conditions, ELISPOT is superior to QFT-G for detecting tuberculosis, irrespective of age, gender, and nutrition.
  • Makoto Nakao, Tetsuya Oguri, Takeshi Suzuki, Eiji Kunii, Yuki Tomita, ...
    2010 年 49 巻 17 号 p. 1857-1862
    発行日: 2010年
    公開日: 2010/09/01
    ジャーナル オープンアクセス
    Objective The novel anthracycline agent amrubicin, has been approved in Japan to treat small and non-small cell lung cancers (SCLC and NSCLC). The present study evaluates the toxicity and effect of amrubicin especially in elderly patients with previously treated lung cancer.
    Patients and Methods This retrospective study analyzed data from 51 patients (<70 years of age, n=29; ≥70 years of age, n=22) with lung cancer (NSCLC, n=21; SCLC, n=30) who were treated with amrubicin at our hospital, between July 2003 and October 2009. All patients had recurrent or refractory lung cancer after one or more chemotherapy regimens. We compared the outcomes of patients younger and older than 70 years of age. Amrubicin (30-40 mg/m2/day) was infused depending on patient performance status and laboratory data over a period of 5 minutes on days 1-3, with courses repeated at intervals of at least 3 weeks. The dose was modified according to myelosuppression.
    Results The mean number of treatment cycles, mean dose and mean interval of amrubicin administration did not significantly differ between patients aged <70 and ≥70 years. The rate of hematological toxicities (≥ Grade 3) also did not significantly differ between the two age groups (leukopenia, 48.3% and 59.1% for age <70 and ≥70 years, p=0.573; neutropenia, 65.5% vs. 77.3%, p=0.536; anemia, 20.7% vs. 22.7%, p=1.000; thrombocytopenia, 13.8% vs. 31.8%, p=0.173). The incidence of grade 2-4 non-hematological toxicities also did not significantly differ between the groups. The response rate of SCLC and disease control rate of NSCLC were similar in the younger and older groups.
    Conclusion Amrubicin monotherapy might be equally tolerated by elderly and younger patients. Further studies are needed to investigate the benefit of amrubicin monotherapy among elderly patients with previously treated lung cancer.
CASE REPORTS
PICTURES IN CLINICAL MEDICINE
LETTERS TO THE EDITORS
feedback
Top